Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ifinatamab Deruxtecan Alone or in Combination in mCRPC (IDeate-Prostate02)
NCT06863272Phase 2Recruiting
- Sponsor
- Merck & Co.
- Start
- Jul 2025
- Primary completion
- Oct 2031
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 19
01
Overview
A Phase 2 trial of ifinatamab deruxtecan in metastatic castration-resistant prostate cancer (mCRPC), sponsored by Merck & Co.. Started Jul 2025; status: recruiting.
02
Drugs
ifinatamab deruxtecan
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NCT06863272.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06863272.